Search

Your search keyword '"Bogaerts, Jan"' showing total 153 results
Start Over Author "Bogaerts, Jan" Publication Year Range Last 10 years
153 results on '"Bogaerts, Jan"'

3. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer

Author

Saesen, Robbe, Van Hemelrijck, Mieke, Bogaerts, Jan, Booth, Christopher M., Cornelissen, Jan J., Dekker, Andre, Eisenhauer, Elizabeth A., Freitas, André, Gronchi, Alessandro, Hernán, Miguel A., Hulstaert, Frank, Ost, Piet, Szturz, Petr, Verkooijen, Helena M., Weller, Michael, Wilson, Roger, Lacombe, Denis, and van der Graaf, Winette T.

Published
2023
Full Text
View/download PDF

4. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Author

Braybrooke, Jeremy, Bradley, Rosie, Gray, Richard, Hills, Robert K, Pan, Hongchao, Peto, Richard, Dodwell, David, McGale, Paul, Taylor, Carolyn, Aihara, Tomohiko, Anderson, Stewart, Blum, Joanne, Cardoso, Fatima, Chen, Xiaosong, Crown, John P, Ejlertsen, Bent, Friedl, Thomas W P, Harbeck, Nadia, Janni, Wolfgang, Jensen, Maj-Britt, Mamounas, Eleftherios, Narui, Kazutaka, Nitz, Ulrike, Norton, Larry, O'Shaughnessy, Joyce, Piccart, Martine, Robert, Nicholas, Shao, Zhi-Ming, Slamon, Dennis, Sparano, Joseph, Watanabe, Toru, Yothers, Greg, Yu, Ke-Da, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Davies, Lucy, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Lui, Hui, Lui, Zulian, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Buzdar, Aman, Suman, Vera J, Hunt, Kelly K, Leonard, Robert C F, Mansi, Janine, Delbaldo, Catherine, Piedbois, Pascal, Quinaux, Emmanuel, Fesl, Christian, Gnant, Michael, Sölkner, Lidija, Steger, Guenther, Eikesdal, Hans Petter, Lønning, Per Eystein, Bee, Valerie, Fung, Helena, Mackey, John, Martin, Miguel, Press, Michael, De Azambuja, Evandro, Gelber, Richard, Regan, Meredith, Di Leo, Angelo, Van Dooren, Veerle, Nogaret, Jean Marie, Bartlett, John, Chen, Bingshu E, Gelmon, Karen, Goss, Paul E, Levine, Mark N, Parulekar, Wendy, Pritchard, Kathleen I, Shepherd, Lois, Berry, Donald, Cirrincione, Constance, Shulman, Lawrence N, Winer, Eric, Gelman, Rebecca S, Harris, Jay R, Henderson, Craig, Shapiro, Charles L, Christiansen, Peer, Ewertz, Marianne, Mouridsen, Henning T, Van Leeuwen, Elise, Linn, Sabine, Van Rossum, Annelot G J, Van Tinteren, Harm, Van Werkhoven, Erik, Goldstein, Lori, Gray, Robert, Eiermann, Wolfgang, Gianni, Luca, Valagussa, Pinuccia, Bogaerts, Jan, Bonnefoi, Herve, Poncet, Coralie, Huovinen, Riikka, Joensuu, Heikki, Bonneterre, Jacques, Fargeot, Pierre, Fumoleau, Pierre, Kerbrat, Pierre, Luporsi, Elisabeth, Namer, Moïse, Carrasco, Eva M, Segui, Miguel Angel, Meisner, Christoph, Loibl, Sibylle, Nekljudova, Valentina, Thomssen, Christoph, Von Minckwitz, Gunter, Kümmel, Sherko, Lopez, Massimo, Vici, Patrizia, Fountzilas, George, Koliou, Georgia, Mavroudis, Dimitrios, Saloustros, Emmanouil, Brain, Etienne, Delaloge, Suzette, Michiels, Stefan, Mathoulin-Pelissier, Simone, Bines, Jose, Sarmento, Roberta M B, Bonadonna, Gianni, Brambilla, Cristina, Rossi, Anna, Bliss, Judith, Coombes, Raoul Charles, Kilburn, Lucy, Marty, Michel, Amadori, Dino, Boccardo, Francesco, Nanni, Oriana, Rubagotti, Alessandra, Scarpi, Emanuela, Masuda, Norikazu, Toi, Masakazu, Ueno, Takayuki, Ishikawa, Takashi, Matsumoto, Koji, Takao, Shintaro, Sommer, Harald, Foroglou, Pericles, Giokas, George, Kondylis, D, Lissaios, Byron, Reinisch, Mattea, Lee, Keun Seok, Nam, Byung-Ho, Ro, Jung Sil, De Matteis, Andrea, Perrone, Francesco, Tang, Gong, Wolmark, Norman, Hozumi, Yasuo, Nomura, Yasuo, Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, De Mastro, Lucia, Venturini, Macro, Delozier, Thierry, Lemonnier, Jerome, Martin, Anne-Laure, Roché, Henri, Spielmann, Marc, Chen, Xiasong, Shen, Kunwei, Albain, Kathy, Barlow, William, Budd, George T, Gralow, Julie, Hayes, Dan, Bartlett-Lee, Peter, Ellis, Paul, Bianco, Angelo Raffaele, De Laurentiis, Michelino, De Placido, Sabino, Wildiers, Hans, Hsu, Limin, Eremin, Oleg, Walker, Leslie G, Ahlgren, Johan, Blomqvist, Carl, Holmberg, Lars, Lindman, Henrik, Asmar, Lina, Jones, Stephen E, Gluz, Oleg, Liedtke, Cornelia, Arriagada, Rodrigo, Bergsten-Nordström, Elizabeth, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Dignam, James, Dowsett, Mitch, Francis, Prudence A, Goetz, Matthew P, Goodwin, Pam, Halpin-Murphy, Pat, Hill, Catherine, Jagsi, Reshma, Mukai, Hirofumi, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Raina, Vinod, Rea, Daniel, Robertson, John, Rutgers, Emiel, Salgado, Roberto, Spanic, Tanja, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Cameron, David, Bergh, Jonas, and Swain, Sandra M

Published
2023
Full Text
View/download PDF

5. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

Author

Delaloge, Suzette, Piccart, Martine, Rutgers, Emiel, Litière, Saskia, van 't Veer, Laura J, van den Berkmortel, Franchette, Brain, Etienne, Dudek-Peric, Aleksandra, Gil-Gil, Miguel, Gomez, Patricia, Hilbers, Florentine S, Khalil, Zaman, Knox, Susan, Kuemmel, Sherko, Kunz, Georg, Lesur, Anne, Pierga, Jean-Yves, Ravdin, Peter, Rubio, Isabel T, Saghatchian, Mahasti, Smilde, Tineke J, Thompson, Alastair M, Viale, Giuseppe, Zoppoli, Gabriele, Vuylsteke, Peter, Tryfonidis, Konstantinos, Poncet, Coralie, Bogaerts, Jan, and Cardoso, Fatima

Subjects
Genetics, Rare Diseases, Breast Cancer, Clinical Trials and Supportive Activities, Human Genome, Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Anthracyclines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Capecitabine, Docetaxel, Female, Humans, Middle Aged, Prospective Studies, MINDACT investigators and the TRANSBIG Consortium, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeMINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of MammaPrint may safely avoid adjuvant chemotherapy. A second random assignment (R-C) compared docetaxel-capecitabine with an anthracycline-based regimen.Patients and methodsR-C randomly assigned patients 1:1 between standard anthracycline-based regimens, with or without taxanes (control) and experimental docetaxel 75 mg/m2 intravenously plus oral capecitabine 825 mg/m2 two times per day for 14 days (DC) every 3 weeks for 6 cycles. The primary end point was disease-free survival (DFS). Secondary end points included overall survival and safety.ResultsOf 2,832 patients, 1,301 (45%) were randomly assigned, and 97% complied with R-C assignment. In the control arm, 29.6% only received taxanes (0.5% of N0 patients). DFS events (n = 148) were much less than required (n = 422) as a result of a lower-than-expected accrual and event rate. At 5 years of median follow-up, DFS was not different between DC (n = 652) and control (n = 649; 90.7% [95% CI, 88% to 92.8%] v 88.8% [95% CI, 85.9% to 91.1%]; hazard ratio [HR], 0.83 [95% CI, 0.60 to 1.15]; P = .26). Overall survival (HR, 0.91 [95% CI, 0.54 to 1.53]) and DFS in the clinical high and genomic high-risk subgroup (86.1% v 88.1%; HR, 0.83 [95% CI, 0.58 to 1.21]) were similar in both arms. DC led to more grade 1 neuropathy (27.1% v 11.2%) and more grade 2 hand/foot syndrome (28.5% v 3.3%) and diarrhea (13.7% v 5.8%). Serious cardiac events occurred in 9 patients (control, n = 4; DC, n = 5). Fifty-three patients developed second cancers (control, n = 32; DC, n = 21; leukemia: 2 v 1). Five treatment-related deaths occurred (control, 2 [0.3%]; DC, 3 [0.5%]).ConclusionAlthough underpowered, this second randomization in MINDACT did not show any improvement in outcome or safety with the use of DC compared with anthracycline-based chemotherapy.

Published
2020

6. Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial

Author

Jacob, Laurent, Witteveen, Anke, Beumer, Inès, Delahaye, Leonie, Wehkamp, Diederik, van den Akker, Jeroen, Snel, Mireille, Chan, Bob, Floore, Arno, Bakx, Niels, Brink, Guido, Poncet, Coralie, Bogaerts, Jan, Delorenzi, Mauro, Piccart, Martine, Rutgers, Emiel, Cardoso, Fatima, Speed, Terence, van ’t Veer, Laura, and Glas, Annuska

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Human Genome, Clinical Trials and Supportive Activities, Cancer, Breast Cancer, Clinical Research, Biotechnology, Genetics, Adult, Aged, Biomarkers, Tumor, Breast Neoplasms, Female, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Neoplasm Proteins, Prognosis, Protein Array Analysis, Randomized Controlled Trials as Topic, Transcriptome, Biological sciences, Biomedical and clinical sciences
Abstract

Gene expression data obtained in large studies hold great promises for discovering disease signatures or subtypes through data analysis. It is also prone to technical variation, whose removal is essential to avoid spurious discoveries. Because this variation is not always known and can be confounded with biological signals, its removal is a challenging task. Here we provide a step-wise procedure and comprehensive analysis of the MINDACT microarray dataset. The MINDACT trial enrolled 6693 breast cancer patients and prospectively validated the gene expression signature MammaPrint for outcome prediction. The study also yielded a full-transcriptome microarray for each tumor. We show for the first time in such a large dataset how technical variation can be removed while retaining expected biological signals. Because of its unprecedented size, we hope the resulting adjusted dataset will be an invaluable tool to discover or test gene expression signatures and to advance our understanding of breast cancer.

Published
2020

7. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Author

Piccart, Martine, van 't Veer, Laura J, Poncet, Coralie, Lopes Cardozo, Josephine M N, Delaloge, Suzette, Pierga, Jean-Yves, Vuylsteke, Peter, Brain, Etienne, Vrijaldenhoven, Suzan, Neijenhuis, Peter A, Causeret, Sylvian, Smilde, Tineke J, Viale, Giuseppe, Glas, Annuska M, Delorenzi, Mauro, Sotiriou, Christos, Rubio, Isabel T, Kümmel, Sherko, Zoppoli, Gabriele, Thompson, Alastair M, Matos, Erika, Zaman, Khalil, Hilbers, Florentine, Fumagalli, Debora, Ravdin, Peter, Knox, Susan, Tryfonidis, Konstantinos, Peric, Aleksandra, Meulemans, Bart, Bogaerts, Jan, Cardoso, Fatima, and Rutgers, Emiel J T

Published
2021
Full Text
View/download PDF

8. Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group.

Author

Nakajima, Erica C., Simpson, Amber, Bogaerts, Jan, de Vries, Elisabeth G.E., Do, Richard, Garalda, Elena, Goldmacher, Greg, Kinahan, Paul E., Lambin, Philippe, LeStage, Barbara, Li, Qin, Lin, Frank, Litière, Saskia, Perez-Lopez, Raquel, Petrick, Nicholas, Schwartz, Lawrence, Seymour, Lesley, Shankar, Lalitha, and Laurie, Scott A.

Subjects
RADIOMICS, ANTINEOPLASTIC agents, INDIVIDUALIZED medicine, DRUG development, CLINICAL medicine, ONCOLOGY nursing, CLINICAL trials monitoring
Abstract

Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials. This paper by the RECIST Working Group outlines a path to realize the potential of radiomics as a precision biomarker. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Societal challenges of precision medicine: Bringing order to chaos

Author

Becker, Robert, Beer, Philip, Bergh, Jonas, Bogaerts, Jan, Dovedi, Simon, Fojo, Antonio T., Gerstung, Moritz, Golfinopoulos, Vassilis, Hewitt, Stephen, Hochhauser, Daniel, Juhl, Hartmut, Kinders, Robert, Lillie, Thomas, Herbert, Kim Lyerly, Maheswaran, Shyamala, Mesri, Mehdi, Nagai, Sumimasa, Norstedt, Irene, O'Connor, Daniel, Oliver, Kathy, Oyen, Wim J.G., Pignatti, Francesco, Polley, Eric, Rosenfeld, Nitzan, Schellens, Jan, Schilsky, Richard, Schneider, Erasmus, Senderowicz, Adrian, Tenhunen, Olli, van Dongen, Augustinus, Vietz, Christine, Wilking, Nils, Salgado, Roberto, Moore, Helen, Martens, John W.M., Lively, Tracy, Malik, Shakun, McDermott, Ultan, Michiels, Stefan, Moscow, Jeffrey A., Tejpar, Sabine, McKee, Tawnya, and Lacombe, Denis

Published
2017
Full Text
View/download PDF

12. Supplementary Data1 from Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

Author

Shankar, Lalitha K., primary, Huang, Erich, primary, Litiere, Saskia, primary, Hoekstra, Otto S., primary, Schwartz, Larry, primary, Collette, Sandra, primary, Boellaard, Ronald, primary, Bogaerts, Jan, primary, Seymour, Lesley, primary, and deVries, Elisabeth G.E., primary

Published
2023
Full Text
View/download PDF

15. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

Author

Dittrich, Christian, Kosty, Michael, Jezdic, Svetlana, Pyle, Doug, Berardi, Rossana, Bergh, Jonas, El-Saghir, Nagi, Lotz, Jean-Pierre, Österlund, Pia, Pavlidis, Nicholas, Purkalne, Gunta, Awada, Ahmad, Banerjee, Susana, Bhatia, Smita, Bogaerts, Jan, Buckner, Jan, Cardoso, Fatima, Casali, Paolo, Chu, Edward, Close, Julia Lee, Coiffier, Bertrand, Connolly, Roisin, Coupland, Sarah, De Petris, Luigi, De Santis, Maria, de Vries, Elisabeth G.E., Dizon, Don S., Duff, Jennifer, Duska, Linda R., Eniu, Alexandru, Ernstoff, Marc, Felip, Enriqueta, Fey, Martin F., Gilbert, Jill, Girard, Nicolas, Glaudemans, Andor W.J.M., Gopalan, Priya K., Grothey, Axel, Hahn, Stephen M., Hanna, Diana, Herold, Christian, Herrstedt, Jørn, Homicsko, Krisztian, Jones, Dennie V., Jr, Jost, Lorenz, Keilholz, Ulrich, Khan, Saad, Kiss, Alexander, Köhne, Claus-Henning, Kunstfeld, Rainer, Lenz, H.einz-Josef, Lichtman, Stuart, Licitra, Lisa, Lion, Thomas, Litière, Saskia, Liu, Lifang, Loehrer, Patrick J., Markham, Merry Jennifer, Markman, Ben, Mayerhoefer, Marius, Meran, Johannes G., Michielin, Olivier, Moser, Elizabeth Charlotte, Mountzios, Giannis, Moynihan, Timothy, Nielsen, Torsten, Ohe, Yuichiro, Öberg, Kjell, Palumbo, Antonio, Peccatori, Fedro Alessandro, Pfeilstöcker, Michael, Raut, Chandrajit, Remick, Scot C., Robson, Mark, Rutkowski, Piotr, Salgado, Roberto, Schapira, Lidia, Schernhammer, Eva, Schlumberger, Martin, Schmoll, Hans-Joachim, Schnipper, Lowell, Sessa, Cristiana, Shapiro, Charles L., Steele, Julie, Sternberg, Cora N., Stiefel, Friedrich, Strasser, Florian, Stupp, Roger, Sullivan, Richard, Tabernero, Josep, Travado, Luzia, Verheij, Marcel, Voest, Emile, Vokes, Everett, Von Roenn, Jamie, Weber, Jeffrey S., Wildiers, Hans, and Yarden, Yosef

Published
2016
Full Text
View/download PDF

18. Meta-Analysis of the Test–Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response

Author

Shankar, Lalitha K., primary, Huang, Erich, additional, Litiere, Saskia, additional, Hoekstra, Otto S., additional, Schwartz, Larry, additional, Collette, Sandra, additional, Boellaard, Ronald, additional, Bogaerts, Jan, additional, Seymour, Lesley, additional, and deVries, Elisabeth G.E., additional

Published
2022
Full Text
View/download PDF

19. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial

Author

Donker, Mila, van Tienhoven, Geertjan, Straver, Marieke E, Meijnen, Philip, van de Velde, Cornelis J H, Mansel, Robert E, Cataliotti, Luigi, Westenberg, A Helen, Klinkenbijl, Jean H G, Orzalesi, Lorenzo, Bouma, Willem H, van der Mijle, Huub C J, Nieuwenhuijzen, Grard A P, Veltkamp, Sanne C, Slaets, Leen, Duez, Nicole J, de Graaf, Peter W, van Dalen, Thijs, Marinelli, Andreas, Rijna, Herman, Snoj, Marko, Bundred, Nigel J, Merkus, Jos W S, Belkacemi, Yazid, Petignat, Patrick, Schinagl, Dominic A X, Coens, Corneel, Messina, Carlo G M, Bogaerts, Jan, and Rutgers, Emiel J T

Published
2014
Full Text
View/download PDF

21. Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance

Author

Viale, Giuseppe, Slaets, Leen, de Snoo, Femke A., Bogaerts, Jan, Russo, Leila, van’t Veer, Laura, Rutgers, Emiel J. T., Piccart-Gebhart, Martine J., Stork-Sloots, Lisette, Dell’Orto, Patrizia, Glas, Annuska M., and Cardoso, Fatima

Published
2016
Full Text
View/download PDF

28. 70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer: Updated Results MINDACT

Author

Piccart, Martine, primary, van't Veer, Laura, additional, Poncet, Coralie, additional, Cardozo, Josephine M.N. Lopes, additional, Delaloge, Suzette, additional, Pierga, Jean-Yves, additional, Vuylsteke, Peter, additional, Brain, Etienne, additional, Vrijaldenhoven, Suzan, additional, Neijenhuis, Peter A., additional, Causeret, Sylvian, additional, Smilde, Tineke J., additional, Viale, Guiseppe, additional, Glas, Annuska M., additional, Delorenzi, Mauro, additional, Sotiriou, Christos, additional, Rubio, Isabel T., additional, Kümmel, Sherko, additional, Zoppoli, Gabrielle, additional, Thompson, Alastair M., additional, Matos, Erika, additional, Zaman, Khalil, additional, Hilbers, Florentine, additional, Fumagalli, Debora, additional, Ravdin, Peter, additional, Knox, Susan, additional, Tryfonidis, Konstantinos, additional, Peric, Aleksandra, additional, Meulemans, Bart, additional, Bogaerts, Jan, additional, Cardoso, Fatima, additional, and Rutgers, Emiel J.Th., additional

Published
2020
Full Text
View/download PDF

31. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology

Author

Salgado, Roberto, primary, Solit, David B., additional, Rimm, David L., additional, Bogaerts, Jan, additional, Canetta, Renzo, additional, Lively, Tracy, additional, Lyerly, Kim, additional, Span, Paul N., additional, Bateman-House, Alison, additional, Makady, Amr, additional, Bergmann, L., additional, Nagai, Sumimasa, additional, Smith, Chris, additional, Robson, Mark, additional, Savage, Mary, additional, Voest, Emile, additional, Sweeney, Christopher, additional, Lambin, Philippe, additional, Thomas, Marlene, additional, Harris, Lyndsay, additional, Lacombe, Denis, additional, Massard, Chistophe, additional, Bernards, Rene, additional, Sullivan, Richard, additional, Tejpar, Sabine, additional, Lukinova, Nina, additional, Lyerly, Herbert K., additional, Moore, Helen, additional, Smith, Malcolm A., additional, Yee, Laura, additional, DuBois, Ray, additional, Hahn, William C., additional, Janne, Pasi, additional, Willman, Cheryl L., additional, Rimm, David, additional, Bergmann, Lothar, additional, Cree, Ian A., additional, Hegde, Priti, additional, Hopper, Shirley, additional, Robson, Marc, additional, Ingelman-Sundberg, Magnus, additional, Nichols, Gwen, additional, Maignen, Francois, additional, Besse, Benjamin, additional, Swierzewski, Rafal, additional, Kiermaier, Astrid, additional, Massard, Christophe, additional, Caliguri, Michael, additional, Velculescu, Victor, additional, Foggi, Paolo, additional, Hahn, Willem C., additional, Salgado, Roberto, additional, and Golfinopoulos, Vassilis, additional

Published
2019
Full Text
View/download PDF

32. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Author

Gray, Richard, primary, Bradley, Rosie, additional, Braybrooke, Jeremy, additional, Liu, Zulian, additional, Peto, Richard, additional, Davies, Lucy, additional, Dodwell, David, additional, McGale, Paul, additional, Pan, Hongchao, additional, Taylor, Carolyn, additional, Barlow, William, additional, Bliss, Judith, additional, Bruzzi, Paolo, additional, Cameron, David, additional, Fountzilas, George, additional, Loibl, Sibylle, additional, Mackey, John, additional, Martin, Miguel, additional, Del Mastro, Lucia, additional, Möbus, Volker, additional, Nekljudova, Valentina, additional, De Placido, Sabino, additional, Swain, Sandra, additional, Untch, Michael, additional, Pritchard, Kathleen I, additional, Bergh, Jonas, additional, Norton, Larry, additional, Boddington, Clare, additional, Burrett, Julie, additional, Clarke, Mike, additional, Davies, Christina, additional, Duane, Fran, additional, Evans, Vaughan, additional, Gettins, Lucy, additional, Godwin, Jon, additional, Hills, Robert, additional, James, Sam, additional, Liu, Hui, additional, MacKinnon, Elizabeth, additional, Mannu, Gurdeep, additional, McHugh, Theresa, additional, Morris, Philip, additional, Read, Simon, additional, Wang, Yaochen, additional, Wang, Zhe, additional, Fasching, Peter, additional, Harbeck, Nadia, additional, Piedbois, Pascal, additional, Gnant, Michael, additional, Steger, Guenther, additional, Di Leo, Angelo, additional, Dolci, Stella, additional, Francis, Prue, additional, Larsimont, Denis, additional, Nogaret, Jean Marie, additional, Philippson, Catherine, additional, Piccart, Martine, additional, Linn, Sabine, additional, Peer, Petronella, additional, Tjan-Heijnen, Vivianne, additional, Vliek, Sonja, additional, Slamon, Dennis, additional, Bartlett, John, additional, Bramwell, Vivien H, additional, Chen, Bingshu, additional, Chia, Stephen, additional, Gelmon, Karen, additional, Goss, Paul, additional, Levine, Mark, additional, Parulekar, Wendy, additional, Pater, Joseph, additional, Rakovitch, Eileen, additional, Shepherd, Lois, additional, Tu, Dongsheng, additional, Whelan, Tim, additional, Berry, Don, additional, Broadwater, Gloria, additional, Cirrincione, Constance, additional, Muss, Hyman, additional, Weiss, Raymond, additional, Shan, Yi, additional, Shao, Yong Fu, additional, Wang, Xiang, additional, Xu, Binghe, additional, Zhao, Dong-Bing, additional, Bartelink, Harry, additional, Bijker, Nina, additional, Bogaerts, Jan, additional, Cardoso, Fatima, additional, Cufer, Tanja, additional, Julien, Jean-Pierre, additional, Poortmans, Philip, additional, Rutgers, Emiel, additional, van de Velde, Cornelis, additional, Carrasco, Eva, additional, Segui, Miguel Angel, additional, Blohmer, Jens Uwe, additional, Costa, Serban, additional, Gerber, Bernd, additional, Jackisch, Christian, additional, von Minckwitz, Gunter, additional, Giuliano, Mario, additional, De Laurentiis, Michele, additional, Bamia, Christina, additional, Koliou, Georgia-Angeliki, additional, Mavroudis, Dimitris, additional, A'Hern, Roger, additional, Ellis, Paul, additional, Kilburn, Lucy, additional, Morden, James, additional, Yarnold, John, additional, Sadoon, Mohammad, additional, Tulusan, Augustinus H, additional, Anderson, Stewart, additional, Bass, Gordon, additional, Costantino, Joe, additional, Dignam, James, additional, Fisher, Bernard, additional, Geyer, Charles, additional, Mamounas, Eleftherios P, additional, Paik, Soon, additional, Redmond, Carol, additional, Wickerham, D Lawrence, additional, Venturini, Marco, additional, Bighin, Claudia, additional, Pastorino, Simona, additional, Pronzato, Paolo, additional, Sertoli, Mario Roberto, additional, Foukakis, Theodorus, additional, Albain, Kathy, additional, Arriagada, Rodrigo, additional, Bergsten Nordström, Elizabeth, additional, Boccardo, Francesco, additional, Brain, Etienne, additional, Carey, Lisa, additional, Coates, Alan, additional, Coleman, Robert, additional, Correa, Candace, additional, Cuzick, Jack, additional, Davidson, Nancy, additional, Dowsett, Mitch, additional, Ewertz, Marianne, additional, Forbes, John, additional, Gelber, Richard, additional, Goldhirsch, Aron, additional, Goodwin, Pamela, additional, Hayes, Daniel, additional, Hill, Catherine, additional, Ingle, James, additional, Jagsi, Reshma, additional, Janni, Wolfgang, additional, Mukai, Hirofumi, additional, Ohashi, Yasuo, additional, Pierce, Lori, additional, Raina, Vinod, additional, Ravdin, Peter, additional, Rea, Daniel, additional, Regan, Meredith, additional, Robertson, John, additional, Sparano, Joseph, additional, Tutt, Andrew, additional, Viale, Giuseppe, additional, Wilcken, Nicholas, additional, Wolmark, Norman, additional, Wood, Wiliam, additional, and Zambetti, Milvia, additional

Published
2019
Full Text
View/download PDF

33. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score

Author

Cherny, Nathan I., primary, de Vries, Elisabeth G.E., additional, Dafni, Urania, additional, Garrett-Mayer, Elizabeth, additional, McKernin, Shannon E., additional, Piccart, Martine, additional, Latino, Nicola J., additional, Douillard, Jean-Yves, additional, Schnipper, Lowell E., additional, Somerfield, Mark R., additional, Bogaerts, Jan, additional, Karlis, Dimitris, additional, Zygoura, Panagiota, additional, Vervita, Katerina, additional, Pentheroudakis, George, additional, Tabernero, Josep, additional, Zielinski, Christoph, additional, Wollins, Dana S., additional, and Schilsky, Richard L., additional

Published
2019
Full Text
View/download PDF

36. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Author

Asselain, Bernard, primary, Barlow, William, additional, Bartlett, John, additional, Bergh, Jonas, additional, Bergsten-Nordström, Elizabeth, additional, Bliss, Judith, additional, Boccardo, Francesco, additional, Boddington, Clare, additional, Bogaerts, Jan, additional, Bonadonna, Gianni, additional, Bradley, Rosie, additional, Brain, Etienne, additional, Braybrooke, Jeremy, additional, Broet, Philippe, additional, Bryant, John, additional, Burrett, Julie, additional, Cameron, David, additional, Clarke, Mike, additional, Coates, Alan, additional, Coleman, Robert, additional, Coombes, Raoul Charles, additional, Correa, Candace, additional, Costantino, Joe, additional, Cuzick, Jack, additional, Danforth, David, additional, Davidson, Nancy, additional, Davies, Christina, additional, Davies, Lucy, additional, Di Leo, Angelo, additional, Dodwell, David, additional, Dowsett, Mitch, additional, Duane, Fran, additional, Evans, Vaughan, additional, Ewertz, Marianne, additional, Fisher, Bernard, additional, Forbes, John, additional, Ford, Leslie, additional, Gazet, Jean-Claude, additional, Gelber, Richard, additional, Gettins, Lucy, additional, Gianni, Luca, additional, Gnant, Michael, additional, Godwin, Jon, additional, Goldhirsch, Aron, additional, Goodwin, Pamela, additional, Gray, Richard, additional, Hayes, Daniel, additional, Hill, Catherine, additional, Ingle, James, additional, Jagsi, Reshma, additional, Jakesz, Raimund, additional, James, Sam, additional, Janni, Wolfgang, additional, Liu, Hui, additional, Liu, Zulian, additional, Lohrisch, Caroline, additional, Loibl, Sibylle, additional, MacKinnon, Liz, additional, Makris, Andreas, additional, Mamounas, Eleftherios, additional, Mannu, Gurdeep, additional, Martín, Miguel, additional, Mathoulin, Simone, additional, Mauriac, Louis, additional, McGale, Paul, additional, McHugh, Theresa, additional, Morris, Philip, additional, Mukai, Hirofumi, additional, Norton, Larry, additional, Ohashi, Yasuo, additional, Olivotto, Ivo, additional, Paik, Soon, additional, Pan, Hongchao, additional, Peto, Richard, additional, Piccart, Martine, additional, Pierce, Lori, additional, Poortmans, Philip, additional, Powles, Trevor, additional, Pritchard, Kathy, additional, Ragaz, Joseph, additional, Raina, Vinod, additional, Ravdin, Peter, additional, Read, Simon, additional, Regan, Meredith, additional, Robertson, John, additional, Rutgers, Emiel, additional, Scholl, Suzy, additional, Slamon, Dennis, additional, Sölkner, Lidija, additional, Sparano, Joseph, additional, Steinberg, Seth, additional, Sutcliffe, Rosemary, additional, Swain, Sandra, additional, Taylor, Carolyn, additional, Tutt, Andrew, additional, Valagussa, Pinuccia, additional, van de Velde, Cornelis, additional, van der Hage, Jos, additional, Viale, Giuseppe, additional, von Minckwitz, Gunter, additional, Wang, Yaochen, additional, Wang, Zhe, additional, Wang, Xiang, additional, Whelan, Tim, additional, Wilcken, Nicholas, additional, Winer, Eric, additional, Wolmark, Norman, additional, Wood, William, additional, Zambetti, Milvia, additional, and Zujewski, Jo Anne, additional

Published
2018
Full Text
View/download PDF

37. Societal challenges of precision medicine: Bringing order to chaos

Author

Salgado, Roberto, primary, Moore, Helen, additional, Martens, John W.M., additional, Lively, Tracy, additional, Malik, Shakun, additional, McDermott, Ultan, additional, Michiels, Stefan, additional, Moscow, Jeffrey A., additional, Tejpar, Sabine, additional, McKee, Tawnya, additional, Lacombe, Denis, additional, Becker, Robert, additional, Beer, Philip, additional, Bergh, Jonas, additional, Bogaerts, Jan, additional, Dovedi, Simon, additional, Fojo, Antonio T., additional, Gerstung, Moritz, additional, Golfinopoulos, Vassilis, additional, Hewitt, Stephen, additional, Hochhauser, Daniel, additional, Juhl, Hartmut, additional, Kinders, Robert, additional, Lillie, Thomas, additional, Herbert, Kim Lyerly, additional, Maheswaran, Shyamala, additional, Mesri, Mehdi, additional, Nagai, Sumimasa, additional, Norstedt, Irene, additional, O'Connor, Daniel, additional, Oliver, Kathy, additional, Oyen, Wim J.G., additional, Pignatti, Francesco, additional, Polley, Eric, additional, Rosenfeld, Nitzan, additional, Schellens, Jan, additional, Schilsky, Richard, additional, Schneider, Erasmus, additional, Senderowicz, Adrian, additional, Tenhunen, Olli, additional, van Dongen, Augustinus, additional, Vietz, Christine, additional, and Wilking, Nils, additional

Published
2017
Full Text
View/download PDF

38. Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial.

Author

Cardoso, Fatima, primary, Piccart-Gebhart, Martine J., additional, Rutgers, Emiel J., additional, Litière, Saskia, additional, Van't Veer, Laura, additional, Viale, Giuseppe, additional, Pierga, Jean-Yves, additional, van den Berkmortel, Franchette W.P.J., additional, Brain, Etienne, additional, Gomez, Patricia, additional, Goulioti, Theodora, additional, Knox, Susan, additional, Luporsi, Elisabeth, additional, Nitz, Ulrike, additional, Rubio, Isabel T, additional, Stork, Lisette, additional, Vuylsteke, Peter, additional, TRYFONIDIS, KONSTANTINOS, additional, Bogaerts, Jan, additional, and Delaloge, Suzette, additional

Published
2017
Full Text
View/download PDF

42. Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up

Author

Liu, Lifang, primary, Giusti, Francesco, additional, Schaapveld, Michael, additional, Aleman, Berthe, additional, Lugtenburg, Pieternella, additional, Meijnders, Paul, additional, Hutchings, Martin, additional, Lemmens, Valery, additional, Bogaerts, Jan, additional, and Visser, Otto, additional

Published
2016
Full Text
View/download PDF

43. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

Author

Casali, Paolo G., Bruzzi, P., Bogaerts, Jan, Blay, Jean-Yves, Aapro, M. S., Adamou, A., Berruti, A., Bressington, J., Bruzzi, B., Capocaccia, R., Cardoso, Fatima, Celis, J. E., Cervantes, A., Ciardiello, F., Claussen, C., Coleman, M., Comis, S., Craine, S., Boltz, D. De, Lorenzo, F. De, P, Angelo Dei Tos, Gatta, G., Geissler, J., Giuliani, R., Grande, E., Gronchi, A., Jezdic, S., Jonsson, B., Jost, Lorenz M., Keulen, H., Lacombe, D., Lamory, G., Cam, Y. Le, Priolo, S. Leto di, Licitra, Lisa, Macchia, F., Margulies, A., Marreaud, S., McVie, G., Narbutas, S., Oliver, K., Pavlidis, Nicholas, Pelouchova, J., Pentheroudakis, George, Piccart, M., Pierotti, M. A., Pravettoni, G., Redmond, K., Riegman, P., Ruffilli, M. P., Ryner, D., Sandrucci, S., Seymour, M., Torri, V., Trama, A., Belle, S. Van, Vassal, G., Wartenberg, M., Watts, C., Wilson, A., Yared, W., Pavlidis, Nicholas [0000-0002-2195-9961], and Pentheroudakis, George [0000-0002-6632-2462]

Subjects
Research design, Pathology, Data base, Research methodology, Electronic medical record, Disease, Review, Procedures, Treatment response, Clinical trials, Rare cancers, Clinical Studies as Topic, Humans, Neoplasms, Rare Diseases, Research Design, Hematology, Oncology, Reimbursement, Priority journal, education.field_of_study, Clinical studies as topic, Rare diseases, Europe, Clinical decision making, Human, medicine.medical_specialty, Practice guideline, Case finding, Population, Health care quality, Reviews, Cancer research, Clinical study, SDG 3 - Good Health and Well-being, Conceptual framework, medicine, Tumor marker, Intensive care medicine, education, Antineoplastic activity, Flexibility (engineering), Surrogate endpoint, business.industry, Methodology, Rare cancer, Study design, Cancer survival, Clinical trial, Patient information, Clinical effectiveness, Position paper, Neoplasm, business, Rare disease
Abstract

While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in clinical studies on rare cancers, as well as adaptive trials in general, with their inherent potential of flexibility when properly applied. While clinical studies are the mainstay to test hypotheses, the potential of electronic patient records should be exploited to generate new hypotheses, to create external controls for future studies (when internal controls are unpractical), to study effectiveness of new treatments in real conditions. Framework study protocols in specific rare cancers to stepwisely test sets of new agents, as from the early post-phase I development stage, should be encouraged. Also the compassionate and the off-label settings should be exploited to generate new evidence, and flexible regulatory innovations such as adaptive licensing could convey new agents early to rare cancer patients, while generating evidence. Though validation of surrogate end points is problematic in rare cancers, the use of an updated notion of tumor response may be of great value in the single patient to optimize the use of therapies, all the more the new ones. Disease-based communities, involving clinicians and patients, should be regularly consulted by regulatory bodies when setting their policies on drug approval and reimbursement in specific rare cancers ., While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in clinical studies on rare cancers, as well as adaptive trials in general, with their inherent potential of flexibility when properly applied. While clinical studies are the mainstay to test hypotheses, the potential of electronic patient records should be exploited to generate new hypotheses, to create external controls for future studies (when internal controls are unpractical), to study effectiveness of new treatments in real conditions. Framework study protocols in specific rare cancers to sequentially test sets of new agents, as from the early post-phase I development stage, should be encouraged. Also the compassionate and the off-label settings should be exploited to generate new evidence, and flexible regulatory innovations such as adaptive licensing could convey new agents early to rare cancer patients, while generating evidence. Though validation of surrogate end points is problematic in rare cancers, the use of an updated notion of tumor response may be of great value in the single patient to optimize the use of therapies, all the more the new ones. Disease-based communities, involving clinicians and patients, should be regularly consulted by regulatory bodies when setting their policies on drug approval and reimbursement in specific rare cancers.

Published
2015

44. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative

Author

Bogaerts, Jan, Sydes, Matthew R., Keat, Nicola, McConnell, Andrea, Benson, Al, Ho, Alan, Roth, Arnaud, Fortpied, Catherine, Eng, Cathy, Peckitt, Clare, Coens, Corneel, Pettaway, Curtis, Arnold, Dirk, Hall, Emma, Marshall, Ernie, Sclafani, Francesco, Hatcher, Helen, Earl, Helena, Ray-Coquard, Isabelle, Paul, James, Blay, Jean-Yves, Whelan, Jeremy, Panageas, Kathy, Wheatley, Keith, Harrington, Kevin, Licitra, Lisa, Billingham, Lucinda, Hensley, Martee, McCabe, Martin, Patel, Poulam M., Carvajal, Richard, Wilson, Richard, Glynne-Jones, Rob, McWilliams, Rob, Leyvraz, Serge, Rao, Sheela, Nicholson, Steve, Filiaci, Virginia, Negrouk, Anastassia, Lacombe, Denis, Dupont, Elisabeth, Pauporté, Iris, Welch, John J., Law, Kate, Trimble, Ted, and Seymour, Matthew

Subjects
Cancer Research, International Cooperation, Methodology, Randomised controlled trials, Review, Bayesian, Public-Private Sector Partnerships, Clinical trials, Rare Diseases, Oncology, Research Design, Neoplasms, Rare cancers, Humans, Frequentist, Multi-arm, Randomized Controlled Trials as Topic
Abstract

Background\ud The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers and the most important contributor has been research. Progress in rare cancers has been slower, not least because of the challenges of undertaking research.\ud \ud Settings\ud The International Rare Cancers Initiative (IRCI) is a partnership which aims to stimulate and facilitate the development of international clinical trials for patients with rare cancers. It is focused on interventional – usually randomised – clinical trials with the clear goal of improving outcomes for patients. The key challenges are organisational and methodological. A multi-disciplinary workshop to review the methods used in ICRI portfolio trials was held in Amsterdam in September 2013. Other as-yet unrealised methods were also discussed.\ud \ud Results\ud The IRCI trials are each presented to exemplify possible approaches to designing credible trials in rare cancers. Researchers may consider these for use in future trials and understand the choices made for each design.\ud \ud Interpretation\ud Trials can be designed using a wide array of possibilities. There is no ‘one size fits all’ solution. In order to make progress in the rare diseases, decisions to change practice will have to be based on less direct evidence from clinical trials than in more common diseases.

Published
2014

45. RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.

Author

Litière, Saskia, Isaac, Gaëlle, De Vries, Elisabeth G.E., Bogaerts, Jan, Chen, Alice, Dancey, Janet, Ford, Robert, Gwyther, Stephen, Hoekstra, Otto, Huang, Erich, Lin, Nancy, Liu, Yan, Mandrekar, Sumithra, Schwartz, Lawrence H., Shankar, Lalitha, Therasse, Patrick, Seymour, Lesley, and RECIST Working Group

Published
2019
Full Text
View/download PDF

46. Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques.

Author

Vandenberghe, Sjouke, Duchateau, Luc, Slaets, Leen, Bogaerts, Jan, and Vansteelandt, Stijn

Subjects
PATHOLOGY, CANCER chemotherapy, BREAST cancer patients, MEDIATION therapy, ANTHRACYCLINES
Abstract

The meta-analytic approach is the gold standard for validation of surrogate markers, but has the drawback of requiring data from several trials. We refine modern mediation analysis techniques for time-to-event endpoints and apply them to investigate whether pathological complete response can be used as a surrogate marker for disease-free survival in the EORTC 10994/BIG 1-00 randomised phase 3 trial in which locally advanced breast cancer patients were randomised to either taxane or anthracycline based neoadjuvant chemotherapy. In the mediation analysis, the treatment effect is decomposed into an indirect effect via pathological complete response and the remaining direct effect. It shows that only 4.2% of the treatment effect on disease-free survival after five years is mediated by the treatment effect on pathological complete response. There is thus no evidence from our analysis that pathological complete response is a valuable surrogate marker to evaluate the effect of taxane versus anthracycline based chemotherapies on progression free survival of locally advanced breast cancer patients. The proposed analysis strategy is broadly applicable to mediation analyses of time-to-event endpoints, is easy to apply and outperforms existing strategies in terms of precision as well as robustness against model misspecification. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

47. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Author

Cardoso, Fatima, primary, van’t Veer, Laura J., additional, Bogaerts, Jan, additional, Slaets, Leen, additional, Viale, Giuseppe, additional, Delaloge, Suzette, additional, Pierga, Jean-Yves, additional, Brain, Etienne, additional, Causeret, Sylvain, additional, DeLorenzi, Mauro, additional, Glas, Annuska M., additional, Golfinopoulos, Vassilis, additional, Goulioti, Theodora, additional, Knox, Susan, additional, Matos, Erika, additional, Meulemans, Bart, additional, Neijenhuis, Peter A., additional, Nitz, Ulrike, additional, Passalacqua, Rodolfo, additional, Ravdin, Peter, additional, Rubio, Isabel T., additional, Saghatchian, Mahasti, additional, Smilde, Tineke J., additional, Sotiriou, Christos, additional, Stork, Lisette, additional, Straehle, Carolyn, additional, Thomas, Geraldine, additional, Thompson, Alastair M., additional, van der Hoeven, Jacobus M., additional, Vuylsteke, Peter, additional, Bernards, René, additional, Tryfonidis, Konstantinos, additional, Rutgers, Emiel, additional, and Piccart, Martine, additional

Published
2016
Full Text
View/download PDF

48. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

Author

Dittrich, C., primary, Kosty, M., additional, Jezdic, S., additional, Pyle, D., additional, Berardi, R., additional, Bergh, J., additional, El Saghir, N., additional, Lotz, J.-P., additional, Österlund, P., additional, Pavlidis, N., additional, Purkalne, G., additional, Carraway, Hetty, additional, Lee Close, Julia, additional, Gilbert, Jill, additional, Bokemeyer, Carsten, additional, Cervantes, Andrés, additional, Ohe, Yuichiro, additional, Pless, Miklos, additional, McGregor, Keith, additional, Fumassoli, Katharine, additional, Candiani, Roberta, additional, Bricalli, Gracemarie, additional, Kenny, Tanya, additional, Latino, Nicola, additional, Cogo, Marina, additional, Pavinato, Vanessa, additional, Marchesi, Vanessa, additional, Awada, Ahmad, additional, Banerjee, Susana, additional, Bhatia, Smita, additional, Bogaerts, Jan, additional, Buckner, Jan, additional, Cardoso, Fatima, additional, Casali, Paolo, additional, Chu, Edward, additional, Coiffier, Bertrand, additional, Connolly, Roisin, additional, Coupland, Sarah, additional, De Petris, Luigi, additional, De Santis, Maria, additional, de Vries, Elisabeth G.E., additional, Dizon, Don S., additional, Duff, Jennifer, additional, Duska, Linda R., additional, Eniu, Alexandru, additional, Ernstoff, Marc, additional, Felip, Enriqueta, additional, Fey, Martin F., additional, Girard, Nicolas, additional, Glaudemans, Andor W.J.M., additional, Gopalan, Priya K., additional, Grothey, Axel, additional, Hahn, Stephen M., additional, Hanna, Diana, additional, Herold, Christian, additional, Herrstedt, Jørn, additional, Homicsko, Krisztian, additional, Jones, Dennie V., additional, Jost, Lorenz, additional, Keilholz, Ulrich, additional, Khan, Saad, additional, Kiss, Alexander, additional, Köhne, Claus-Henning, additional, Kunstfeld, Rainer, additional, Lenz, Heinz-Josef, additional, Lichtman, Stuart, additional, Licitra, Lisa, additional, Lion, Thomas, additional, Litière, Saskia, additional, Liu, Lifang, additional, Loehrer, Patrick J., additional, Jennifer Markham, Merry, additional, Markman, Ben, additional, Mayerhoefer, Marius, additional, Meran, Johannes G., additional, Michielin, Olivier, additional, Charlotte Moser, Elizabeth, additional, Mountzios, Giannis, additional, Moynihan, Timothy, additional, Nielsen, Torsten, additional, Öberg, Kjell, additional, Palumbo, Antonio, additional, Alessandro Peccatori, Fedro, additional, Pfeilstöcker, Michael, additional, Raut, Chandrajit, additional, Remick, Scot C., additional, Robson, Mark, additional, Rutkowski, Piotr, additional, Salgado, Roberto, additional, Schapira, Lidia, additional, Schernhammer, Eva, additional, Schlumberger, Martin, additional, Schmoll, Hans-Joachim, additional, Schnipper, Lowell, additional, Sessa, Cristiana, additional, Shapiro, Charles L., additional, Steele, Julie, additional, Sternberg, Cora N., additional, Stiefel, Friedrich, additional, Strasser, Florian, additional, Stupp, Roger, additional, Sullivan, Richard, additional, Tabernero, Josep, additional, Travado, Luzia, additional, Verheij, Marcel, additional, Voest, Emile, additional, Vokes, Everett, additional, Von Roenn, Jamie, additional, Weber, Jeffrey S., additional, Wildiers, Hans, additional, and Yarden, Yosef, additional

Published
2016
Full Text
View/download PDF

49. RECIST 1.1—Update and clarification: From the RECIST committee

Author

Schwartz, Lawrence H., primary, Litière, Saskia, additional, de Vries, Elisabeth, additional, Ford, Robert, additional, Gwyther, Stephen, additional, Mandrekar, Sumithra, additional, Shankar, Lalitha, additional, Bogaerts, Jan, additional, Chen, Alice, additional, Dancey, Janet, additional, Hayes, Wendy, additional, Hodi, F. Stephen, additional, Hoekstra, Otto S., additional, Huang, Erich P., additional, Lin, Nancy, additional, Liu, Yan, additional, Therasse, Patrick, additional, Wolchok, Jedd D., additional, and Seymour, Lesley, additional

Published
2016
Full Text
View/download PDF

50. RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

Author

Schwartz, Lawrence H., primary, Seymour, Lesley, additional, Litière, Saskia, additional, Ford, Robert, additional, Gwyther, Stephen, additional, Mandrekar, Sumithra, additional, Shankar, Lalitha, additional, Bogaerts, Jan, additional, Chen, Alice, additional, Dancey, Janet, additional, Hayes, Wendy, additional, Hodi, F. Stephen, additional, Hoekstra, Otto S., additional, Huang, Erich P., additional, Lin, Nancy, additional, Liu, Yan, additional, Therasse, Patrick, additional, Wolchok, Jedd D., additional, and de Vries, Elisabeth, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results